Changed transferrin sialylation in Parkinson's disease.
Variation in the sialylation pattern of transferrin was studied in serum and cerebrospinal fluid (CSF) of 90 patients with Parkinson's disease (PD), dementing and non-dementing, de novo and treated, and was compared with the variation observed in a group of 21 age-matched healthy controls. In serum and CSF of PD patients the proportional contribution of the different sialo-transferrins was independent of sex or dementia. However, a significant shift was found towards the more sialylated fractions for serum transferrin in both de novo and treated PD patients. This shift was not observed for CSF transferrin. The contribution of the tau-transferrin fraction, reduced in de novo PD patients, returns on treatment to the level observed for healthy controls. These observations may be important, as the degree of sialylation of transferrin in serum and CSF plays a role in the homeostasis of iron, and suggest that alterations in transferrin sialylation may play a role in the pathophysiology of PD.
van Kamp
G J
GJ
Department of Clinical Chemistry, Free University Hospital, Amsterdam, The Netherlands.
Mulder
K
K
Kuiper
M
M
Wolters
E C
EC
D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019158:N-Acetylneuraminic Acid; D010300:Parkinson Disease / Q000097:blood* / Q000134:cerebrospinal fluid / Q000235:genetics; D012794:Sialic Acids / Q000097:blood* / Q000134:cerebrospinal fluid / Q000235:genetics; D014168:Transferrin / Q000134:cerebrospinal fluid / Q000737:chemistry* / Q000235:genetics
D012794:Sialic Acids; D014168:Transferrin; D019158:N-Acetylneuraminic Acid